Accurate dermatopathologic interpretation is critical to the work of the cutaneous oncologist.1 Changes in the delivery of health care have altered the relationship between the dermatologist and his or her dermatopathologist.2,3 Third party payors often mandate that biopsy specimens be sent to their approved list of pathology laboratories, which may not have the requisite expertise in diagnosing cutaneous tumors.4 We discuss a series of cases that were misdiagnosed in these laboratories, highlighting the impact on patient welfare and cost containment.
Olhoffer IH, Lazova R, Leffell DJ. Histopathologic Misdiagnoses and Their Clinical Consequences. Arch Dermatol. 2002;138(10):1381-1383. doi:10.1001/archderm.138.10.1378